Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-SARS-CoV-2 monoclonal antibody AZD3152

A long-acting neutralizing human monoclonal antibody derived from B cells of convalescent patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and directed against SARS-CoV-2, that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration, anti-SARS-CoV-2 monoclonal antibody AZD3152 neutralizes SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	AZD 3152 AZD-3152 AZD3152

anti-SARS-CoV-2 monoclonal antibody AZD3152

Search NCI's Drug Dictionary